肿瘤标志物联合临床参数鉴别肺腺体前驱病变及肺腺癌浸润性
苏州市立医院(南京医科大学附属苏州医院)
目的 评价癌胚抗原(CEA)、鳞状细胞癌抗原(SCCA)、神经元特异性烯醇化酶(NSE)、糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)、人附睾蛋白4(HE4)联合年龄、肿瘤最大径鉴别Ⅰ期肺腺癌与肺腺体前驱病变(PGL)及判断浸润程度的效能。方法 比较87例Ⅰ期肺腺癌与30例PGL患者上述指标,采用受试者工作特征(ROC)曲线评价诊断效能,并比较PGL、微浸润性腺癌(MIA)及浸润性腺癌(IAC)三组差异。结果 Ⅰ期肺腺癌组年龄、最大径、CEA、HE4、CYFRA21-1均高于PGL组(P<0.05);联合诊断曲线下面积(AUC)为0.852。年龄、最大径、CEA、HE4随浸润程度增加,CYFRA21-1仅IAC组高于PGL组。结论联合检测可辅助鉴别PGL与Ⅰ期肺腺癌并判断浸润程度。
Objective To evaluate carcinoembryonic antigen(CEA), squamous cell carcinoma antigen(SCCA), neuron-specific enolase(NSE), carbohydrate antigen 125(CA125), cytokeratin 19 fragment(CYFRA21-1), human epididymis protein 4(HE4), age, and maximum tumor diameter for differentiating stage I lung adenocarcinoma from pulmonary glandular precursor lesions(PGL) and assessing invasion. Methods Eight indicators were compared between 87 adenocarcinoma and 30 PGL cases. Receiver operating characteristic(ROC) curves assessed diagnostic performance. PGL, minimally invasive adenocarcinoma(MIA), and invasive adenocarcinoma(IAC) were compared. Results Age, maximum diameter, CEA, HE4, and CYFRA21-1 were higher in adenocarcinoma than those in the PGL group(P<0.05). Combined area under the curve(AUC) was 0.852. Age, maximum diameter, CEA, and HE4 increased with invasion. CYFRA21-1 was higher only in IAC than PGL. Conclusion Combined detection may assist differential diagnosis between PGL and stage I lung adenocarcinoma and invasion assessment.
引用本文
按标准格式复制,或导出到文献管理软件参考文献
共 19 条- [1]Zhang Y,Vaccarella S,Morgan E,et al. Global variations in lung cancer incidence by histological subtype in 2020:a population-based study[J]. Lancet Oncol,2023,24(11):1206-1218.
- [2]Nicholson A G,Tsao M S,Beasley M B,et al. The2021 WHO Classification of Lung Tumors:Impact of Advances Since 2015[J]. J Thorac Oncol,2022,17(3):362-387.
- [3]Yotsukura M,Asamura H,Motoi N,et al. Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung[J]. J Thorac Oncol,2021,16(8):1312-1320.
- [4]赵燕霞,麦热哈吧·哈力克,魏雪梅.血清标志物水平对非小细胞肺癌患者的早期诊断效能分析[J].中国医刊,2025,60(4):391-394.
- [5]钟结兴,陈土日,招志翔.六项肿瘤标志物对肺腺癌的辅助诊断价值分析[J].实用癌症杂志,2024,39(12):2026-2031.
- [6]廖聪,甘甜,汪靖婷,等.基于肺腺癌肿瘤标志物建立临床分期诊断模型[J].武汉大学学报(医学版),2025,46(8):1040-1045.
- [7]杨雅静,霍丽静,于芳,等.血清HE4和IL-6对非小细胞肺癌的诊断价值研究[J].中国煤炭工业医学杂志,2023,26(6):583-587.
- [8]Smolarz B,Łukasiewicz H,Samulak D,et al. Lung Cancer-Epidemiology,Pathogenesis,Treatment and Molecular Aspect(Review of Literature)[J].International journal of molecular sciences,2025,26(5):2049.
- [9]Inamura K. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma:Tumor Initiation and Progression[J]. International journal of molecular sciences,2018,19(4):1-17.
- [10]陈永华,陈坚,林了一,等.基于人工智能鉴别CT表现为混合磨玻璃结节的腺体前驱病变与微浸润腺癌的模型建立[J].重庆医学,2025,54(8):1848-1853.
- [11]Bertolaccini L,Casiraghi M,Uslenghi C,et al. Advances in lung cancer surgery:the role of segmentectomy in early-stage management[J]. Expert Rev Respir Med,2024,18(9):669-675.
- [12]Mankidy B J,Mohammad G,Trinh K,et al. High risk lung nodule:A multidisciplinary approach to diagnosis and management[J]. Respiratory medicine,2023,214:107277.
- [13]Liu X,Xu Y,Shu J,et al. Preoperative CT and Radiomics Nomograms for Distinguishing Bronchiolar Adenoma and Early-Stage Lung Adenocarcinoma[J].Academic radiology,2025,32(2):1054-1066.
- [14]沈凡含,姚远凡,杜飞行,等.应用年龄-时期-队列模型分析2009-2023年浙江省奉化区肺癌发病趋势[J].上海预防医学,2025,1-8.
- [15]张雨馨,沈夏波,赵伟,等.年轻肺癌患者的临床特征和分子特征的回顾性研究[J].现代肿瘤医学,2022,30(12):2169-2176.
- [16]Niimi T,Samejima J,Wakabayashi M,et al. Tenyear follow-up outcomes of limited resection trial for radiologically less-invasive lung cancer[J]. Jpn J Clin Oncol,2024,54(4):479-488.
- [17]廖蓉蓉. NSE、CEA、CYFRA21-1、SCCA水平联合检测诊断肺癌的价值研究[J].现代诊断与治疗,2024,35(22):3414-3416.
- [18]张敏,刘浩,赵铁锁,等.血清CEA、SCCA、NSE、Cyfra21-1在非小细胞肺癌诊断及分型中的应用价值[J].中国医药指南,2025,23(16):74-76.
- [19]刘婷.血清HE4、CA153、CA724、NSE水平对非小细胞肺癌患者预后的评估价值[J].中国卫生工程学,2025,34(1):116-117.
| 文章编号 | 2026-07-028(期号内编号) |
|---|---|
| 栏目 | 临床药物与手术治疗 |
| 作者 | 黄安康;吴献华;成刚;王长兴;吴剑;鄂浩然;王子辰;王宇恒;彭彦彰;龚永生 |
| 作者单位 | 苏州市立医院(南京医科大学附属苏州医院) |
| 通信邮箱 | gongshuishengone@aliyun.com; |
| 中图分类号 | R734.2 |
| 卷期页码 | 2026, 2(07): 109-112 |
| 发布时间 | 2026-10-15 |
| 出版时间 | 2026-10-15 |
| 引用信息 | [1]黄安康,吴献华,成刚,等.肿瘤标志物联合临床参数鉴别肺腺体前驱病变及肺腺癌浸润性[J].疾病预防与控制,2026,2(07):109-112. |
| 全文地址 | 在知网查看该文(kns.cnki.net) |
| 数据抓取时间 | 2026-11-03T03:30:56 |